Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008942 | 0.84 | POLB (0.43) | MAPTALDH1A1TP53LMNAPOLB | |
| SCHEMBL2006506 | 0.82 | ANPEP (0.49) | MAPTALDH1A1TP53PTGDR2LMNA | |
| SCHEMBL2009399 | 0.81 | ALDH1A1 (0.36) | MAPTALDH1A1TP53PTGDR2LMNA | |
| SCHEMBL2006817 | 0.79 | ALDH1A1 (0.36) | MAPTALDH1A1TP53LMNAPOLB | |
| SCHEMBL661521 | 0.70 | BRD4 (0.41) | MAPTALDH1A1POLB | |
| SCHEMBL2010777 | 0.70 | L3MBTL1 (0.36) | TP53TSHRPOLB | |
| SCHEMBL2007119 | 0.64 | CYP1A2 (0.66) | MAPTALDH1A1LMNAPOLB | |
| SCHEMBL2825476 | 0.64 | TP53 (0.41) | MAPTALDH1A1TP53PTGDR2LMNA | |
| SCHEMBL2824115 | 0.62 | ANPEP (0.48) | ALDH1A1TP53PTGDR2LMNAANPEP | |
| SCHEMBL2823619 | 0.62 | ANPEP (0.48) | PTGDR2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | MAPT 387/4885OPRK1 2195/4885OPRD1 1852/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | MAPT 387/4885OPRK1 2195/4885OPRD1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.